RESUMEN
OBJECTIVE: To assess the condylar growth activity (CGA) with quantitative bone single photon emission computed tomography/computed tomography (SPECT/CT) to establish reference values of maximum standardized uptake value (SUVmax) and cutoff values for identifying active unilateral condylar hyperplasia (UCH) in different ages. METHODS: We analyzed the CGA of 58 UCH patients and that of 125 volunteers as a control group by SUVmax of quantitative bone SPECT/CT imaging. The SUVmax and the uptake difference between bilateral condyles among different age groups were analyzed. SUVmax cutoff values for detecting active condyle were calculated by receiver operating characteristic curve analysis. RESULTS: The condylar SUVmax in 10-19, 20-29, 30-39, 40-49 and 50-59 years old groups of volunteers were 6.24 ± 1.39, 4.76 ± 0.98, 3.23 ± 0.64, 3.00 ± 0.61 and 2.90 ± 0.53, respectively. The uptake difference between bilateral condyles in the control group was 3.84% ± 1.71%. The affected condylar SUVmax was significantly higher than that of the contralateral condyle in active UCH patients (6.03 ± 2.85 vs. 3.96 ± 1.07; Z = -5.264; P = 0.000). SUVmax of the affected condyles in active UCH patients was not statistically higher than condylar SUVmax in the corresponding age group (6.03 ± 2.85 vs. 5.50 ± 1.41; Z = -0.173; P = 0.863). SUVmax of the unaffected condyles was significantly lower than condylar SUVmax in the corresponding age group (3.96 ± 1.07 vs. 5.50 ± 1.41; Z = -5.833; P = 0.000). SUVmax cutoff values for identifying active condyle were 6.26 and 4.53 in patients of 13-19 and 20-29 years old, respectively. CONCLUSIONS: The condylar SUVmax varied with age. Different cutoff values of condylar SUVmax should be employed for diagnosing active UCH for patients in different ages.
Asunto(s)
Cóndilo MandibularRESUMEN
Oral gene therapy has emerged as a potential optimal treatment for ulcerative colitis (UC). Nucleic acid drugs possessing versatility can not only inhibit inflammation but realize colon mucosal healing, fulfilling the clinical objective of UC therapy. However, the effective accumulation and distribution of oral nucleic acid drugs in the colon remain a considerable challenge. Furthermore, current delivery systems pay more attention to the accumulation of nucleic acid drugs in the colon, while the distribution of nucleic acid drugs in the colon, which plays a key role in the UC treatment, never catches the attention of researchers. Here, we used miR-320 as a model nucleic acid drug to develop a kind of multistage-responsive nanocomplexes (MSNs) based on polymeric nanocapsules and alginate. MSNs possess the pH responsiveness in the stomach, the enzyme responsiveness in the colonic lumen, and the redox responsiveness in the cytoplasm. In vivo imaging results showed that MSNs reach the colon within 2 h and effectively release miR-320 nanocapsules in the colonic lumen. The nanocapsules can further deliver miR-320 to the submucosal layer and even the muscular layer. Moreover, MSNs decreased the activity of myeloperoxidase and proinflammatory cytokines and exhibited anti-inflammatory activity by inhibiting the phosphorylation of IκBα and AKT, reducing colonic inflammation and enhancing mucosal repair. Therefore, MSNs can successfully alleviate UC by improving the accumulation and distribution of oral nucleic acid drugs in the colon, promoting the clinical translational application of nucleic acid drugs in the treatment of UC.